Leapfrog Micro-Infusion Device

Device Mercator MedSystems, Inc.
Total Payments
$45,418
Transactions
26
Doctors
13
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $45,418 26 13

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $43,645 14 96.1%
Consulting Fee $1,000 1 2.2%
Food and Beverage $773.06 11 1.7%

Payments by Type

Research
$43,645
14 transactions
General
$1,773
12 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Perivenous Dexamethasone Therapy: Examing Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT Mercator MedSystems, Inc. $43,645 5

Top Doctors Receiving Payments for Leapfrog Micro-Infusion Device

Doctor Specialty Location Total Records
, MD Diagnostic Radiology Pittsburgh, PA $16,500 3
, M.D Vascular Surgery Darien, CT $11,085 3
, M.D Cardiovascular Disease Mckinney, TX $6,900 1
Unknown Bartlesville, OK $4,579 5
, M.D Internal Medicine Columbus, OH $3,631 2
, M.D Vascular Surgery Washington, DC $2,000 2
, MD Surgery Norfolk, VA $220.81 2
, M.D Vascular & Interventional Radiology Orange, CA $138.32 1
, M.D Pulmonary Disease Lebanon, NH $77.34 1
, MD Surgery Charlotte, NC $73.89 2
, MD Cardiovascular Disease Houma, LA $53.73 1
, M.D Vascular Surgery Houston, TX $53.73 1
, M.D Specialist Columbus, OH $52.35 1
, MD Undersea and Hyperbaric Medicine Palo Alto, CA $52.35 1

About Leapfrog Micro-Infusion Device

Leapfrog Micro-Infusion Device is a device associated with $45,418 in payments to 13 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Mercator MedSystems, Inc..

Payment data is available from 2024 to 2024. In 2024, $45,418 was paid across 26 transactions to 13 doctors.

The most common payment nature for Leapfrog Micro-Infusion Device is "Unspecified" ($43,645, 96.1% of total).

Leapfrog Micro-Infusion Device is associated with 1 research study, including "Perivenous Dexamethasone Therapy: Examing Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT" ($43,645).